申请人:Kowa Company, Ltd.
公开号:US08273766B2
公开(公告)日:2012-09-25
The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.
本发明涉及一种特定的四氢异喹啉化合物,该化合物可作为趋化因子受体3(CCR3)拮抗剂,并且包含该化合物作为活性成分的药物组合物。本发明的四氢异喹啉化合物可用于治疗或预防CCR3参与的疾病。